Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 408-420, 2024.
Artigo
em Inglês
| WPRIM
| ID: wpr-1007638
ABSTRACT
As pancreatic cancer (PC) is highly malignant, its patients tend to develop metastasis at an early stage and show a poor response to conventional chemotherapies. First-line chemotherapies for PC, according to current guidelines, include fluoropyrimidine- and gemcitabine-based regimens. Accumulating research on drug resistance has shown that biochemical metabolic aberrations in PC, especially those involving glycolysis and glutamine metabolism, are highly associated with chemoresistance. Additionally, lipid metabolism is a major factor in chemoresistance. However, emerging compounds that target these key metabolic pathways have the potential to overcome chemoresistance. This review summarizes how PC develops chemoresistance through aberrations in biochemical metabolism and discusses novel critical targets and pathways within cancer metabolism for new drug research.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Pancreáticas
/
Resistencia a Medicamentos Antineoplásicos
/
Carcinoma Ductal Pancreático
/
Linhagem Celular Tumoral
/
Desoxicitidina
/
Gencitabina
/
Reprogramação Metabólica
Limite:
Humanos
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2024
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS